Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats

Neuroscience

Volumn 77, Issue 3, 1997, Pages 745-752

  Lapchak, P A ^a   Miller, P J ^a   Jiao, S ^a  

^a AMGEN INC   (United States)

Author keywords

Alzheimer's disease; cholinergic neurons; dopaminergic neurons; neurotrophic factor; Parkinson's disease

Indexed keywords

CHOLINE ACETYLTRANSFERASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; RECOMBINANT GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; RECOMBINANT NERVE GROWTH FACTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADOLESCENT; AGED; AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0031550611     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(96)00492-7     Document Type: Article

References (54)

1. 1. Agid Y. (1995) Le veiellissement, la malade et al mort des cellules nerveuses. Bull. Acad. Natle. Med. 179, 1193-1207.
2. 2. Alberch J., Perez-Navarro E., Arenas E. and Marsal J. (1991) Involvement of nerve growth factor and its receptor in the regulation of cholinergic function in aged rats. J. Neurochem. 57, 1483-1487.
3. 3. Araujo D. M., Lapchak P. A., Meaney M. J., Collier B. and Quirion R. (1990) Effects of aging on nicotinic and muscarinic autoreceptor function in the rat brain: relationship to presynaptic cholinergic markers and binding sites. J. Neurosci. 10, 3069-3078.
4. 4. Araujo D. M., Lapchak P. A. and Hefti F. (1993) Effects of chronic basic fibroblast growth factor administration to rats with partial fimbrial transections on presynaptic cholinergic parameters and muscarinic receptors in the hippocampus: comparison with nerve growth factor. J. Neurochem. 61, 899-910.
5. 5. Arenas E., Trupp M., Akerud P. and Ibanez C. F. (1995) GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 15, 1465-1471.
6. 6. Bowenkamp K. E., Hoffman A. F., Gerhardt G. A., Henry M. A., Biddle P. T., Hoffer B. J. and Granholm A. C. E. (1995) Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. comp. Neurol. 355, 479-489.
7. 7. Bowenkamp K. E., David D., Lapchak P. A., Henry M. A., Granholm A.-C., Hoffer B. J. and Mahalik T. J. (1996) 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat - a possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Expl Brain Res. 111, 1-7.
8. 8. Bowenkamp K. E., Lapchak P. A., Hoffer B. J. and Pickford P. C. (1996) Glial cell line-derived neurotrophic factor reverses motor impairment in aged rats. Neurosci. Lett. 211, 81-84.
9. 125I]nerve growth factor by cholinergic neurons and down-regulated TrkA expression in the medial septum of aged rats. Neuroscience 623, 625-629.
10. 9. Cross A. J., Crow T. J., Johnson J. A., Perry E. K., Blessed G. and Tomlinson B. (1984) Studies on the neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer type. J. neurol. Sci. 64, 198-217.
11. 9a. Cullen M., Baker M. and Pelleymounter M. (1996) Glial cell line-derived neurotrophic factor (GDNF) improves spatial learning in aged F344 and Long-Evans Rats. Soc. Neurosci. Abstr. 22, 767.2.
12. 10. Dournaud P., Delaere P., Hauw J. J. and Epelbaum J. (1995) Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease. Neurobiol. Agng 16, 817-823.
13. 11. Emerich D. F., McDermott P., Krueger P., Banks M., Zhao J., Marszalkowski J., Frydel B., Winn S. R. and Sanberg P. R. (1993) Locomotion of aged rats: relationship to neurochemical but not morphological changes in nigrostriatal dopaminergic neurons. Brain Res. Bull. 32, 477-486.
14. 12. Finch C. E. (1990) Longevity, Senescence and the Genome. University of Chicago Press, Chicago.
15. 13. Fischer W., Bjorklund A., Chen K. and Gage F. H. (1991) NGF improves spatial memory in aged rodents as a function of age. J. Neurosci. 11, 1889-1906.
16. 14. Fischer W., Wictorin K., Bjorklund A., Williams L. R., Varon S. and Gage F. H. (1987) Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329, 65-68.
17. 15. Fong T. G., Neff N. H. and Hadjiconstantinou M. (1995) Systemic administration of GM1 ganglioside increases choline acetyltransferase activity in the brain of aged rats. Expl Neurol. 132, 157-161.
18. 16. Fonnum F. (1975) A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24, 407-409.
19. 17. Gibson G. E., Peterson C. and Jenden D. J. (1981) Brain acetylcholine synthesis declines with senescence. Science 213, 674-676.
20. 18. Gillard E. R., Dang D. Q. and Stanley B. G. (1983) Evidence that neuropeptide Y and dopamine in the perifornical hypothalamus interact antagonistically in the control of food intake. Brain Res. 628, 128-136.
21. 19. Goldman, J. and Cote, L (1991) Aging of the brain: dementia of the Alzheimer's type. In Principles of Neural Science, 3rd edn, (eds Kandel E. R., Schwartz J. H. and Jessell T. M.). Elsevier Science Publishing Co., Inc. New York.
22. 20. Goldman J. E., Calingasan N. Y. and Gibson G. E. (1994) Aging and the brain. Curr. Opin. Neurol. 7, 287-293.
23. 21. Haba K., Ogawa N., Kawata M. and Mori A. (1988) A method for parallel determination of choline acetyltransferase and muscarnic cholinergic receptors: application in aged-rats. Neurochem. Res. 13, 951-955.
24. + overflow of dopamine in the striatum. Soc. Neurosci. Abstr. 21, 225.5.
25. 23. Hellweg R., Fischer W., Hock C., Gage F. H., Bjorklund A. and Thoenen H. (1990) Nerve growth factor levels and choline acetyltransferase activity in the brain of aged rats with spatial memory impairments. Brain Res. 537, 123-130.
26. 24. Hoffer B. J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L. F. and Gerhardt G. A. (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182, 107-111.
27. 25. Hudson J., Granholm A. C., Gerhardt G. A., Henry M. A., Hoffman A., Biddle P., Leela N. S., Mackerlova L., Lile J. D., Collins F. and Hoffer B. J. (1995) Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36, 425-432.
28. 26. Kalivas P. W. and Stewart J. (1991) Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev. 16, 223-244.
29. 27. Lanius R. A., Pasqualotto B. A. and Shaw C. (1983) Age-dependent expression, phosphorylation and function of neurotransmitter receptors: pharmacological implications. Trends pharmac. Sci. 14, 403-408.
30. 28. Lapchak P. A. (1992) Therapeutic potential for nerve growth factor in Alzheimer's disease: insights from pharmacological studies using lesioned central cholinergic neurons. Rev. Neurosci. 3, 109-119.
31. 29. Lapchak P. A. (1996) Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev. Neurosci 7, 165-176.
32. 30. Lapchak P. A. and Hefti F. (1992) BDNF and NGF treatment in lesioned rats: effects on cholinergic function and weight gain. NeuroReport 3, 405-408.
33. 31. Lapchak P. A. and Araujo D.M. (1994) NGF suppression of weight gain in adult female rats correlates with decreased hypothalamic cholecystokinin levels. Brain Res. 655, 12-16.
34. 32. Lapchak P. A., Beck K. D., Araujo D. M., Irwin I., Langsten J. W. and Hefti F. (1993) Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection. Neuroscience 53, 639-650.
35. 125I-GDNF in the rat and primate CNS following an icv injection: correlation with the behavioral and pharmacological activities of icv administered GDNF in Parkinson's disease models. ASNT P52.
36. 34. Lapchak P. A., Jiao S., Miller P. J., Williams L., Cummins V., Inouye G., Matheson C. R. and Yan Q. (1996) Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule to treat neurodegenerative diseases. Cell Tiss. Res. 286, 179-189.
37. 34a. Lapchak P. A., Miller P. J., Jiao S., Araujo D. M., Hilt D. and Collins F. (1996) Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration 5, 197-205.
38. 35. Lin L. H., Doherty D.H., Lile J. D., Bektesh S. and Collins F. (1993) GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130-1132.
39. 36. Luine V. N., Renner K. J., Heady S. and Jones K. J. (1986) Age and sex-dependent decrease in ChAT in basal forebrain nuclei. Neurobiol. Agng 7, 193-198.
40. 37. Martin D., Miller G., Fischer N., Dix D. and Cullen T. (1996) Glial derived neurotrophic factor: the lateral cerebral ventricle is an effective site of administration for stimulation of the nigrostriatal system. Eur. J. Neurosci 8, 1249-1255.
41. 38. Miller R. and Beninger R. J. (1991) On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine. Prog. Neurobiol. 36, 229-256.
42. 39. Nakamura S. and Ohno T. (1995) Spatial learning impairment in aged rats: comparing between aged basal forebrain lesioned and normal aged rats. Behav. Brain Res. 70, 69-76.
43. 40. Ogawa N., Asanuma M., Kondo Y., Nishibayashi S. and Mori A. (1994) Reduced choline acetyltransferase activity and muscarine M1 receptor levels in aged Fisher 344 rat brains did not parallel their respective mRNA levels. Brain Res. 658, 87-92.
44. 41. Olson L. (1993) NGF and the treatment of Alzheimer's disease. Expl Neurol. 124, 5-15.
45. 3H]tyrosine by charcoal. Life Sci. 39, 2185-2189.
46. 43. Rylett R. J., Goddard S., Schmidt S. M. and Williams L. R. (1993) Acetylcholine synthesis and release following continous intracerebral administration of NGF in adult and aged Fisher-344 rats. J. Neurosci. 13, 3956-3963.
47. 44. Sastry R. B. V., Janson V. E., Jaiswal N. and Tayeb O. S. (1983) Changes in enzymes of the cholinergic system and acetylcholine release in the cerebra of aging male Fischer rats. Pharmacology 26, 61-72.
48. 45. Shults C. W., Shinm C., Ernestom C. and Martin D. (1996) Effects of intrastriatal injections of glial cell line-derived neurotrophic factor (GDNF) in rats. Expl Neurol. (in press).
49. 46. Stoessl A. J., Martin-Iverson M. T., Barth T. M., Dourish C. T. and Iversen S. D. (1989) Effects of ageing on the behavioral responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy. Brain Res. 495, 20-30.
50. 47. Tomac A., Widenfalk J., Lin L. F. H., Kohno T., Ebendal T., Hoffer B. J. and Olson L. (1995) Retrograde axonal transport of GDNF in the adult nigro-striatal system suggests a trophic role in the adult. Proc. natn. Acad. Sci. U.S.A. 92, 8274-8278.
51. 48. Walter S. B. and London E. (1989) Choline acetyltransferase activity and muscarinic binding in brain regions of aging Fischer 344 rats. Neurochem. Int. 14, 483-490.
52. 49. Williams L. R. and Rylett R. J. (1990) Exogenous nerve growth factor increases the activity of high-affinity choline uptake and choline acetyltransferase in brain of Fisher 344 male rats. J. Neurochem. 55, 1042-1049.
53. 50. Williams L. R. (1991) Hypophagia is induced by intraventricular administration of nerve growth factor. Expl Neurol. 113, 31-37.
54. 51. Williams L. R., Inouye G., Cummins V. and Pelleymounter M. A. (1996) Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to nerve growth factor and brain-derived neurotrophic factor. J. Pharmac. exp. Ther. 277, 1140-1151.